Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Lenrispodun. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 1.00 |
| ▸ | PDE2A | O00408 | 3/20 | 1.00 |
| ▸ | PDE8A | O60658 | 3/20 | 1.00 |
| ▸ | PDE5A | O76074 | 3/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 3/20 | 1.00 |
| ▸ | PDE11A | Q9HCR9 | 3/20 | 1.00 |
| ▸ | PDE7B | Q9NP56 | 3/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 1.00 |
| ▸ | PDE9A | O76083 | 2/20 | 1.00 |
| ▸ | PDE1B | Q01064 | 1/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 1/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lenrispodun SCHEMBL30357428 | 1.00 | PDE4A (1.00) | PDE4APDE2APDE8APDE5APDE3B | |
| Lenrispodun SCHEMBL21225678 | 1.00 | PDE4A (1.00) | PDE4APDE2APDE8APDE5APDE3B | |
| Lenrispodun SCHEMBL10201342 | 0.96 | PDE4A (1.00) | PDE4APDE2APDE8APDE5APDE3B | |
| Lenrispodun SCHEMBL18211963 | 0.96 | PDE4A (1.00) | PDE4APDE2APDE8APDE5APDE3B | |
| Lenrispodun SCHEMBL16324627 | 0.96 | PDE4A (1.00) | PDE4APDE2APDE8APDE5APDE3B | |
| Lenrispodun SCHEMBL18771113 | 0.96 | PDE4A (1.00) | PDE4APDE2APDE8APDE5APDE3B | |
| Lenrispodun SCHEMBL29415040 | 0.96 | PDE4A (1.00) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL20341393 | 0.95 | PDE4A (0.97) | PDE4APDE2APDE8APDE5APDE3B | |
| Lenrispodun SCHEMBL17766669 | 0.94 | PDE4A (0.92) | PDE4APDE2APDE8APDE5APDE3B | |
| SCHEMBL8060473 | 0.92 | PDE4A (0.88) | PDE4APDE2APDE8APDE5APDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338385-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-10-26 | — | — | US | claimed |
| US-12605384-B2 | Uses | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| EP-3746081-B1 | PDE1 INHIBITORS FOR USE TO TREAT CARDIAC FAILURE AND CARDIOTOXICITY | INTRA CELLULAR THERAPIES INC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-11839614-B2 | Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression | INTRA-CELLULAR THERAPIES, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230338385-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20210205307-A1 | NOVEL USES | INTRA-CELLULAR THERAPIES, INC. (US) | 2021-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205307-A1 | NOVEL USES | ADORA2A, ADORA2B, ADORA1 | PDE4A 12/4885PDE2A 6/4885PDE8A 65/4885 |
| US-11839614-B2 | Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression | ADORA2A, ADORA1, ADORA2B | PDE4A 17/4885PDE2A 6/4885PDE8A 78/4885 |
| US-20230338385-A1 | NOVEL USES | ADORA2A, ATP2A1, ADORA2B | PDE4A 11/4885PDE2A 4/4885PDE8A 34/4885 |
| US-12605384-B2 | Uses | PDE2A, NPR1, PDE7A | PDE4A 13/4885PDE2A 1/4885PDE8A 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.